Head-to-head · WeighScore
AM Rx vs Dr. Gillis' Wellness Center
The verdict
Dr. Gillis' Wellness Center takes it — 67/100 to 49.9/100.
Dr. Gillis' Wellness Center grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Dr. Gillis' Wellness Center is a Maine-based clinic (Oakland) offering nationwide telehealth for GLP-1 weight loss. It prescribes semaglutide, tirzepatide, and retatrutide in both injectable and subli
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | AM Rx | Dr. Gillis' Wellness Center |
|---|---|---|
| WeighScore | 49.9/100 | 67/100 |
| Grade | C | C |
| Scorecard rank | #490 | #169 |
| Semaglutide | $151/mo (quarterly plan, plus a separate fee, compounded) | $149/mo (starting dose, compounded) |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #490 · C
Strengths
- Insurance coordination for brand-name GLP-1s — as low as $25/mo
- All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
- HSA and FSA accepted
- Video visits available with providers averaging 10+ years' experience
- Compounded semaglutide from $151/mo on the quarterly plan
Where it loses points
- Active FTC/DOJ lawsuit over deceptive billing and subscription practices
- Novo Nordisk false-advertising lawsuit (Aug 2025)
- Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
- Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #169 · C
Strengths
- Sublingual ODT tablets offered as needle-free alternative
- Broad GLP-1 menu: semaglutide, tirzepatide, and retatrutide
- Transparent pricing: $150 starting dose, plans from $149/mo
- Led by board-certified physician/surgeon with 25+ years experience
- No contracts; flexible weekly, bi-weekly, or monthly cadence
Where it loses points
- Specific dose-tier pricing beyond starting plan not detailed
- Compounded vs brand not explicitly stated for all meds
- Smaller clinic vs national telehealth brands
- State licensing list not published
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.